Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Astrid Jullion

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|May 16, 2008
Pharmacokinetic parameters estimation using adaptive Bayesian P-splines modelsAstrid Jullion, Philippe Lambert, Benoit Beck, et al.
The AAPS Journal|February 8, 2021
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201Nelson Guerreiro, Astrid Jullion, Stephane Ferretti, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 21, 2022
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatmentMélanie Wilbaux, David Demanse, Yi Gu, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I studyKosmas Kretsos, Georg Golor, Astrid Jullion, et al.
Clinical Pharmacology and Therapeutics|September 22, 2022
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)Mélanie Wilbaux, Shu Yang, Astrid Jullion, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 4, 2022
Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug DispositionBirk Poller, David Pearson, Luc Alexis Leuthold, et al.
British Journal of Cancer|June 18, 2021
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studiesSebastian Bauer, George D Demetri, Ensar Halilovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib StudyAlbiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
Cancer Research|August 24, 2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|May 16, 2008
Pharmacokinetic parameters estimation using adaptive Bayesian P-splines modelsAstrid Jullion, Philippe Lambert, Benoit Beck, et al.
The AAPS Journal|February 8, 2021
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201Nelson Guerreiro, Astrid Jullion, Stephane Ferretti, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 21, 2022
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatmentMélanie Wilbaux, David Demanse, Yi Gu, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I studyKosmas Kretsos, Georg Golor, Astrid Jullion, et al.
Clinical Pharmacology and Therapeutics|September 22, 2022
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)Mélanie Wilbaux, Shu Yang, Astrid Jullion, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 4, 2022
Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug DispositionBirk Poller, David Pearson, Luc Alexis Leuthold, et al.
British Journal of Cancer|June 18, 2021
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studiesSebastian Bauer, George D Demetri, Ensar Halilovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib StudyAlbiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
Cancer Research|August 24, 2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, et al.
Pageof 1